PH.D. DEGREE IN PHARMACEUTICAL SCIENCES

Mansoor A. Khan, Ph.D.
Professor and Vice Dean
Texas Higher Education Coordination Board Site Visit
May 7, 2019
OUTLINE

• RCOP – By the Numbers
• Why Ph.D. in Pharmaceutical Sciences?
• Program Elements
• Research Preparedness and Infrastructure
• Q&A
BY THE NUMBERS: RCOP

- Campuses: 2
- Current students: 461
- Former Students: 759
- Faculty: 52
- Staff: 36
- Research Associates: 21
- Preceptors: >1260
## BIG IDEAS FROM SPRING 2016 FACULTY RETREAT

<table>
<thead>
<tr>
<th>Transformational Idea</th>
<th>Green</th>
<th>Orange</th>
<th>Pink</th>
</tr>
</thead>
<tbody>
<tr>
<td>Develop strong graduate (PhD) and residency programs</td>
<td>24</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Product development center (convergence integration with TAMU)</td>
<td>13</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>State of the art teaching/learning center</td>
<td>11</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>College run mini-pharmacy/clinics</td>
<td>11</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Collaborate with community health centers &amp; pharmacy services</td>
<td>10</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>International scholars program - faculty recruitment</td>
<td>10</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Establish pediatric and geriatric centers of excellence</td>
<td>5</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Work with Clinicians/Pharmacist for solutions to adverse product evaluations</td>
<td>2</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>Personalized medicine kiosk</td>
<td>1</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Change curriculum to a 2 + 2 program</td>
<td>13</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Internationally collaborative pharmacy graduate program</td>
<td>9</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Increase student quality</td>
<td>8</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Move college closer to a teaching hospital</td>
<td>5</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>World renowned through global pharmacy</td>
<td>5</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Transition COP into problem based learning curriculum</td>
<td>4</td>
<td>6</td>
<td>3</td>
</tr>
</tbody>
</table>
MISSION AND OBJECTIVES

The mission of the Ph.D. program in Pharmaceutical Sciences (PHSC) is to provide a comprehensive knowledge base that leads to drug discovery, design, and development of pharmaceutical dosage forms through basic and applied research in pharmaceutical sciences.

Some objectives of the PHSC program are:

• To provide a meaningful and important course of study that is currently unavailable in Texas A&M University.

• To train and create pharma and biotech entrepreneurs who will know how to leverage the vast knowledge and infrastructure of Texas A&M programs in engineering, veterinary medicine, Agri-Life, medicine, dentistry, biomedical sciences, physical and life sciences, business, and how to help advance drug and medication policies.

• To provide students with specific experiences in conceptual and technical research areas in the pharmaceutical sciences, e.g., pharmaceutics, medicinal chemistry, pharmacology, pharmacy administration, and basic sciences.
Five Year Ph.D. Pharmaceutical Sciences Enrolment in National and Texas Universities

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nation</td>
<td>3086</td>
<td>3094</td>
<td>3266</td>
<td>3109</td>
<td>3051</td>
</tr>
<tr>
<td>UT Austin</td>
<td>124</td>
<td>91</td>
<td>125</td>
<td>119</td>
<td>106</td>
</tr>
<tr>
<td>U of Houston</td>
<td>65</td>
<td>63</td>
<td>65</td>
<td>58</td>
<td>57</td>
</tr>
<tr>
<td>Texas Tech</td>
<td>38</td>
<td>38</td>
<td>37</td>
<td>38</td>
<td>43</td>
</tr>
<tr>
<td>Texas Southern</td>
<td>16</td>
<td>18</td>
<td>19</td>
<td>18</td>
<td>18</td>
</tr>
</tbody>
</table>

- Less than 10% of qualified applicants accepted in these programs
- Employment is almost 100% within 3 months of graduation (details provided in proposal)

Five Year Ph.D. Pharmaceutical Sciences Graduations in National and Texas Universities

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nation</td>
<td>565</td>
<td>589</td>
<td>497</td>
<td>471</td>
<td>450</td>
</tr>
<tr>
<td>UT Austin</td>
<td>19</td>
<td>12</td>
<td>21</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>U of Houston</td>
<td>7</td>
<td>13</td>
<td>7</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Texas Tech</td>
<td>7</td>
<td>5</td>
<td>5</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Texas Southern</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Please note that Texas A&M University System does not have ANY ENROLMENT or GRADUATION since we don’t have the PhD program in pharmaceutical sciences. More than 60 institutions of higher education in US have PHD degrees in pharmaceutical sciences already.
INTERNAL SUPPORT

• “We anticipate that the proposed degree (Ph.D. in PharmSci) would be complementary to the Ph.D. in Biomedical Sciences offered by CVM” -- Dean Eleanor Green, Vet Medicine

• “A graduate program in pharmaceutical science in Rangel College has the potential to unite enterprise and education, making the State of Texas an epicenter for pharmaceutical development”. “I firmly believe the formation of a graduate program in pharmaceutical science will be a game changer…” Dean Katherine Banks -- Engineering

• “The area of pharmaceutical sciences is clearly the missing puzzle for formulations development at Texas A&M”
  – Dean Mark Hussey – Agri-Life, Now President of TAMUK

• “I am writing to offer my highest support and best wishes for this worthy endeavor” – Former Dean Paul Ogden, Interim Senior VP and COO HSC, now Provost in TTUHSC El Passo

• “The HSC is fully committed to the success of the new Ph.D. program in pharmaceutical sciences”. “I offer my strongest support for the establishment of this new doctoral program in the Texas A&M Irma Lerma Rangel College of Pharmacy. – Dean Carrie Byington, Exec Vice President and Dean COM

• “The letter represents my strongest endorsement for the proposal being submitted by your college to develop a Doctor of Philosophy (PhD) program in pharmaceutical sciences) – Provost Anderson – TAMUK, Now President University of Maryland, Eastern Shore.
EXTERNAL SUPPORT

• “Pharmaceutical product development strategies have dramatically changed after FDA’s call for modernization… I believe that newer programs have a much better opportunity to integrate various disciplines.” – Diane Burgess, AAPS President (2002), CRS President (2010), Editor IJP.

• I am very pleased to see a much-needed multidisciplinary approach with concrete plans to connect pharmacy, engineering, basic science, medicine, and veterinary medicine… I support this proposal without reservations – Ajaz Hussain, President NIPTE.
EXTERNAL SUPPORT – TEXAS PHARMA INDUSTRY

“The Mylan research and Development group includes more than 2900 scientists worldwide…” Often times we face challenges with the lack of availability of talented PhD level scientists.” Mylan Labs, San Antonio

“Please be assured of my full support for the mission of this new Ph.D. program in pharmaceutical sciences. I am confident that Allergan, Santen, Alcon/Novartis, Pfizer and other companies in the region will tremendously benefit with qualified graduates.” Mike Garrst, Former Senior VP of Allergan.
Texas A&M Proposal

- Enrolment projections (10 students per year)
- Academics (in proposal)
- Admission standards (in proposal)
- Program degree requirements

Table 2: Semester Credit Hour Requirements by Category

<table>
<thead>
<tr>
<th>Category</th>
<th>SCH Entering with a Bachelor’s</th>
<th>SCH Entering with a Master’s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required Courses</td>
<td>26</td>
<td>18</td>
</tr>
<tr>
<td>Prescribed Electives</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Electives</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>Dissertation</td>
<td>38</td>
<td>28</td>
</tr>
<tr>
<td>Other (Specify, e.g., internships, clinical work, residencies)</td>
<td>Lab rotations, seminars (2)</td>
<td>Lab rotations, seminars (2)</td>
</tr>
<tr>
<td><strong>TOTAL</strong>†</td>
<td><strong>90</strong></td>
<td><strong>60</strong></td>
</tr>
</tbody>
</table>

†Texas Education Code 61.059 (l) limits funding for doctoral students to 99 SCH. Programs may be allowed to require additional SCH, if there is a compelling academic reason.
# REQUIRED COURSES FOR ALL STUDENTS

<table>
<thead>
<tr>
<th>Prefix and Number</th>
<th>Required/Core Course Title</th>
<th>SCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHSC 610*</td>
<td>Biotech drugs and vaccine products</td>
<td>4</td>
</tr>
<tr>
<td>PHSC 611*</td>
<td>Drug delivery and formulations</td>
<td>4</td>
</tr>
<tr>
<td>PHSC 612*</td>
<td>Principles of drug actions</td>
<td>4</td>
</tr>
<tr>
<td>PHSC 613*</td>
<td>Laboratory rotations</td>
<td>3 + 3</td>
</tr>
<tr>
<td>PHSC 621*</td>
<td>Biostatistics or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 622*</td>
<td>Professionalism and ethics in research or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 623*</td>
<td>Seminar</td>
<td>1+1</td>
</tr>
<tr>
<td>Prefix and Number</td>
<td>Prescribed Elective Course Title</td>
<td>SCH</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------------------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>PHSC 724*</td>
<td>Principles of pharmacology and toxicology</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 725*</td>
<td>Biopharmaceutics and pharmacokinetics</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 731*</td>
<td>Process and product development or equivalent</td>
<td>2</td>
</tr>
<tr>
<td>PHSC 732*</td>
<td>Controlled and targeted drug delivery</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 733*</td>
<td>Drug degradation and product stability or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 734*</td>
<td>Vaccine delivery</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 735*</td>
<td>Industrial pharmacy</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 736*</td>
<td>Physical pharmacy</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 737*</td>
<td>Transdermal and topical drug delivery</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 738*</td>
<td>Cosmetic development</td>
<td>2</td>
</tr>
<tr>
<td>PHSC 739*</td>
<td>Pediatric dosage forms</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 741*</td>
<td>Analytical/Bioanalytical techniques and validation</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 742*</td>
<td>High throughput training in drug discovery and screening</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 743*</td>
<td>Polymer chemistry or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 744*</td>
<td>Chemometrics and big data management or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 689*</td>
<td>Topics in pharmaceutical science</td>
<td>1, 2, 3</td>
</tr>
<tr>
<td>PHSC 752*</td>
<td>Nanotechnology for biomedical applications</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 753*</td>
<td>PK/PD and drug metabolism or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 754*</td>
<td>Toxicokinetics and predictive toxicology</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 755*</td>
<td>In-vitro/in-vivo simulations and modeling</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 756*</td>
<td>Advanced pharmacology</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 757*</td>
<td>Herbal drugs or equivalent</td>
<td>3</td>
</tr>
<tr>
<td>PHSC 758*</td>
<td>Research in pharmaceutical science</td>
<td>1, 2, 3</td>
</tr>
<tr>
<td>PHSC 691*</td>
<td>Dissertation research</td>
<td>3</td>
</tr>
</tbody>
</table>
TEXAS A&M HUMAN CLINICAL RESEARCH FACILITY

HCRF includes:

• Facilities to conduct training and rehabilitation research
• Conference rooms and offices
• 12 beds for overnight research studies
• A metabolic kitchen
• A pharmacy compounding and sterile products room
• 4 procedure and research examination rooms
• DEXA and resting energy expenditure rooms
TEXAS A&M NATIONAL CENTER FOR THERAPEUTICS MANUFACTURING

NCTM bioprocess labs include:

• Upstream lab
• Downstream lab
• Analytical lab
• Cell culture lab

NCTM offers:

• Workforce development
• Operation-Technician training
• Continuing education courses
• BioFORCE STEM summer academies
TEXAS A&M INSTITUTE FOR PRECLINICAL STUDIES (TIPS)
tips.tamu.edu
TIPS building amenities include:

- GLP compliant clinical pathology laboratory
- Three 600 ft² surgical suites, plus a hybrid imaging suite
- Large 150 person auditorium for meetings/training
- Conference rooms and sponsor work rooms w/video feed to labs
PRODUCT DEVELOPMENT FACILITY IN COLLEGE STATION

pharmacy.tamhsc.edu
DR. RAHMAN’S/DR. KHAN’s LAB AT RANGEL COLLEGE OF PHARMACY

**Analytical Facility**

The Analytical Lab and Research Facility incorporates state-of-the-art laboratory equipment for performing chemical analyses, developing methods to aid in research, online-monitoring of process and product development.

**Manufacturing Facility**

Our Manufacturing facility is a prototype of a pharmaceutical industry equipped with machines for making oral solid dosage forms. Training is provided for faculty and graduate students in equipment operation and research techniques from interdisciplinary departments.
Product Characterization Facility
Dosage forms characterization facility incorporates state-of-the-art laboratory equipment’s like Agilent Dissolution USP apparatus I and II Model 708-D5 with autosampler. Three Agilent HPLC system, Model 1260 Infinity II HPLC’s with autosampler and RI and PDA detectors. Waters UPLC-MS, Model Acquity UPLC QSM with Acquity PDA Detector and QDa detector. TA.XTPlus Texture Analyzer (Stable Microsystems Ltd). Laser diffraction particle sizer with solid and liquid samples measuring capability (PSA 1190, Anton Paar)

Additive Manufacturing Facility
In addition to conventional manufacturing our facility is equipped with state of the art 3D printing machines like Selective Laser sintering (SLS) and Fused deposition modelling (FDM) for printing oral solid dosage forms for pediatrics. Training is provided for faculty and graduate students in equipment operation and research techniques from interdisciplinary departments.
The Palakurthi Laboratory is interested in applying nanotechnology principles in drug delivery and targeting.

The lab is working on the design and development of nanoparticle systems using lipids, proteins and polymers for targeting anticancer drugs, and drug combinations, to cancer cells for effective reversal of drug resistance in the cancer cells, particularly breast and ovarian cancers.

A hybrid plasmid has been developed for Enzyme directed prodrug therapy for breast cancer.

The lab has developed nanoparticles using zein, a corn protein, for oral delivery of drugs to treat inflammatory bowel disease (IBD).

A novel in vitro drug release method for testing the bioequivalence of topical ophthalmic products is under investigation.
Zhu’s lab focuses on: (i) design of the stimuli-sensitive nanocarriers/drug conjugates in response to local stimuli, such as pH and matrix metalloproteinases (MMP); (ii) design of the novel nanomaterials to enhance the drug’s cellular bioavailability through increasing cellular uptake and inhibiting multidrug resistance (such as drug efflux); and (iii) design of the novel polymers/nanomaterials for intracellular and organelle targeting.
HIV/AIDS and Drugs of Abuse Implicates Neuro-AIDS

Research Focuses on:

- Metabolic Deficits Impact CNS Dysfunction
- Role in Acquit phase proteins and Inflammasome
- Epigenetic Modification and Mitochondrial Biogenesis
Nanoconfinement Gold mediated Oncothermia

Gold Particle-in-Particle (PIP), in which gold nanoparticles are physically confined within PLGA-PEG nanoparticles, significantly enhances thermal energy production by red-shifting the gold nanoparticle’s absorption spectra via a mechanism in which we call Nanoconfinement-Induced Therapeutic Enhancement (NITE). NITE mediated Gold PIPs significantly suppress breast, skin, and multi-drug resistant tumors.

Active targeting Biological Nanoparticles

An innovative strategy for cancer therapy based on: (i) simple and economic protocol of mass production of pure immune cell exosomes, (ii) synthesis of active targeting moieties, (iii) physical labeling of ligands for active targeting therapy, and (iv) maximum intracellular delivery of exogenous drugs with no or minimum off-targeting side effects.
MAJETI-LAB
DRUG & DISEASE-NO BAR

- Well supported by basic and clinical collaborators
- Large or Small, we deliver ALL! It’s all about DELIVERY!

Amphoterin B; Atorvastatin
Cyclosporine A; Paclitaxel
Doxorubicin; Insulin
Tamoxifen etc

Curcumin; Coenzyme Q₁₀
Ellagic acid; EGCG, Urolithin A

E₂
272.4 Da

b-gal
465 kDa

TBI
Epilepsy
Gulf War illness
Alzheimer’s Stroke

Diabetes
Postmenopausal-dyslipidemia
Hypertension
Myocardial Ischemia

HIV
IBD
AKI
Lupus
Fungal infection
Leishmaniasis

Cancer (breast, lung, ovarian)
Arthritis
DR. CHOU DHURY’S RESEARCH

Research includes:

1) Early epigenetic biomarkers in preeclampsia and diabetes
2) Effect of plastics in pregnancy complications and diabetes and obesity
3) Anti-HIV condom material development
4) Reversal of metabolic diseases via nutraceuticals
5) Epigenetic regulation during exercise
6) Epigenetic instrumentation development
Dr. Elmageed laboratory is focusing on translational research in the field of oncology and therapeutics including prostate, breast cancer and melanoma. This encompasses molecular and cellular biology and therapeutic approaches using in vitro and in vivo mouse model systems as well as human specimens. His laboratory has been actively involved in research training of international graduate students, scholars, postdoctoral fellows and junior faculty members at Texas A&M Health Sciences Center.

Kumar’s lab focuses on:

• (i) Understand the mechanism of intestinal restitution during inflammatory bowel disease (IBD) and development of intestinal-specific therapeutics.

• (ii) Understand gut-brain communication during obesity, and develop gut-dysbiosis associated therapeutics for Alzheimer’s disease/mental health.

• (iii) Understand gut-liver communication during obesity associated hepatic steatosis.
DR. NUTAN’S RESEARCH LAB

- Liposomal delivery system of gene
- Solid lipid nanoparticles of curcumin for antitumor activity
- Biodegradable in situ injectable preparations for extended delivery of various drugs
THE LU LABORATORY AT COLLEGE OF PHARMACY

- The Lu lab is a medicinal chemistry laboratory working in the interface of organic synthesis and pharmaceutical sciences.

- The lab is engaged in the discovery of potential therapeutics for the treatment of cancer, neurodegenerative diseases and various disorders associated with the endocannabinoid system such as pain, drug-addiction and obesity.

- The lab has filed three patent applications, and one is in the stage of PCT application.

- The lab currently has three senior scientists, one research assistant, several student workers and two consultants. (Profs. K.C. Nicolaou and Apurba Bhattacharya).

Fume hoods & Automatic Flash Chromatography
Advion Mass Spectrometer
Chiral HPLC
Computer Modeling Station
The ongoing research in Dr. Ali’s lab focuses on computational design and chemical synthesis of potential antitumor agents by applying Targeted Cancer Therapy approach. Through this approach the aggressive and resistant HER2+ve breast cancer is targeted by integrating multidisciplinary drug design approaches to improve drug specificity. In addition, Dr. Ali has been actively involved in mentoring 4 Ph.D students (Joint grants) and 17 Pharm-D students (independent research study) at RCOP.

(A) Molecular overlay view of Abl, c-kit, FAK, Src, B-raf, and FLT1 kinases showing ATP binding site in yellow surface view.
(B) The binding mode of compound 9e into Abl kinase.
Dr. Lixian Zhong’s lab focuses on Pharmacoeconomics and Outcomes Research in the disease area of oncology, neurological diseases and opioid use disorders.

- The lab is engaged in using large national and statewide healthcare data and economic modeling to study:
  - Cost-effectiveness of novel interventions
  - Healthcare costs and resource utilizations
  - Comparative outcomes associated with different treatment options
MICHAEL J. MILLER, RPH, DRPH, FAPHA

• As a researcher, I use both primary and secondary data to study and refine methods to measure and identify those at risk for low health literacy, evaluate the literacy-sensitivity of pharmacy processes and environments, and identify interventions that improve health literacy and ensure optimal medication use and risk communication.

• My primary areas of clinical interest include cardiovascular-related disease, rheumatology, depression, and, most recently, infectious disease.

• From a process perspective, I also have a strong interest in treatment guideline concordance with respect to medication management as well as disparities in healthcare practices.
DR. MISHRA’S LAB

Dr. Mishra’s lab focus:

- Role of drug transporters during chronic inflammatory diseases.

Confocal microscope
Dr. Juan Bustamante

Research Area
- Liver regeneration
- Maternal liver growth
- Growth hormone

Techniques
- proteomics
- molecular
- cellular biology
- in vitro
- mouse model
Thanks & Gig ‘em!